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Abstract
Background:  Immunosuppression by gliomas contributes to tumor progression and treatment
resistance. It is not known when immunosuppression occurs during tumor development but it likely
involves cross-talk among tumor cells, tumor-associated macrophages and microglia (TAMs), and
peripheral as well as tumor-infiltrating lymphocytes (TILs).
Results: We have performed a kinetic study of this immunomodulation, assessing the dynamics of immune
infiltration and function, within the central nervous system (CNS) and peripherally. PDGF-driven murine
glioma cells were injected into the white matter of 13 mice. Four mice were sacrificed 13 days post-
injection (dpi), four mice at 26 dpi, and five mice at 40 dpi. Using multiparameter flow cytometry, splenic
T cells were assessed for FoxP3 expression to identify regulatory T cells (Tregs) and production of IFN-γ
and IL-10 after stimulation with PMA/ionomycin; within the CNS, CD4+ TILs were quantified, and TAMs
were quantified and assessed for TNF-α and IL-10 production after stimulation with LPS. Peripheral
changes associated with tumor development were noted prior to effects within the CNS. The percentage
of FoxP3+ regulatory T cells (Tregs) increased by day 26, with elevated frequencies throughout the
duration of the study. This early increase in Tregs was paralleled by an increase in IL-10 production from
Tregs. At the final time points examined (tumor morbidity or 40 dpi), there was an increase in the
frequency of TAMs with decreased capacity to secrete TNF-α. An increase in TIL frequency was also
observed at these final time points.
Conclusion: These data provide insight into the kinetics of the immunosuppressive state associated with
tumor growth in a murine model of human gliomas. Functional impairment of TAMs occurs relatively late
in the course of GBM tumor growth, potentially providing a window of opportunity for therapeutic
strategies directed towards preventing their functional impairment.
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Background
Despite decades of research and clinical experience with
surgical, radiotherapeutic, chemotherapeutic, and other
therapy modalities, prognosis for malignant glioma has
remained dismal, with median survival for WHO Grade
IV tumors still being approximately one year despite
aggressive treatment [1,2]. Immunotherapy represents a
theoretically promising treatment [3-6], though early
experiences with glioma immunotherapy have been dis-
appointing [7,8]. In the past, these disappointments
would have been attributed to the "immune privilege" of
the brain [9], citing the relative impermeability of the
blood-brain barrier to immune cells, lack of CNS lym-
phatics, and the relative immunoincompetence of micro-
glia, the resident CNS macrophage. However, more
recently, evidence of immunity to exogenous as well as
endogenous antigens in the CNS [10] suggests that the
interaction between the CNS and immune system is much
more complex [11,12]. Immunosuppression by gliomas
may contribute to tumor progression and treatment resist-
ance. It is not known when immunosuppression occurs
during tumor development but it likely involves cross-talk
among tumor cells, tumor-associated macrophages and
microglia (TAMs), and peripheral as well as tumor-infil-
trating lymphocytes (TILs) [13,14].
In humans, we and others [15,16] have observed that up
to a third of the GBM tumor mass can consist of TAMs.
However, these GBM-infiltrating TAMs are reported to be
functionally impaired [16-19]. As these cells represent the
large immune infiltrate in human gliomas, understanding
the mechanisms by which TAMs are rendered non-func-
tional represents an important step in developing effective
immunotherapy for this disease.
We and others have shown in humans and animal models
that the lymphocyte population from within gliomas is
larger than in unaffected brain, and exhibits functional
impairment as well [20-22] (CEM, unpublished observa-
tions). Glioma-associated immunosuppression has also
been observed in peripheral immune cell populations,
notably Tregs, a T cell population that plays a role in the
maintenance of tolerance to self antigen [23]. Evidence
suggests that Tregs may play an important role in the
maintenance of self-tolerance in neoplastic disease,
including GBM [21,24-27].
The dynamics by which this immunomodulation occurs
has not been systematically studied throughout the course
of tumor development. Humans cannot be studied until
clinical diagnosis, a relatively late timepoint in the dis-
ease. There is also a paucity of animal research describing
the kinetics of such effects [19]. Accordingly, using a
PDGF-driven syngeneic murine glioma model, we have
performed a kinetic study of this immunomodulation,
assessing the dynamics of immune infiltration and func-
tion, both within the tumor and peripherally.
Results
In an initial series of experiments, we aimed to determine
the relative frequencies of tumor-infiltrating lymphocytes
(TILs) versus tumor-associated macrophages/microglia
(TAMs). In this preliminary study, TAMs were defined as
cells isolated from 10 dpi ex vivo tumor specimens express-
ing CD45 but not expressing CD3; in our more extensive
follow up study, however, we defined TAMs as cells
expressing CD45 and CD11b, a marker for cells of mye-
loid lineage that includes monocytes, macrophages, and
microglia (cells expressing these markers comprise poten-
tial antigen-presenting cells (APCs) within the tumor
bed). TILs were defined as CD3+CD45+, and may include
a variety of T cell subsets, including both CD4+ T helper
cells and CD8+ cytotoxic T lymphocytes (CTLs). After
excluding cells with extreme side and forward scatter
properties, the frequencies of these two cell populations
were quantified (Figure 1.A). Noteworthy was the much
higher frequency of TAMs relative to TILs in all animals
examined (Figure 1.B). Not surprisingly, greater numbers
of TILs were apparent when there were also greater num-
bers of TAMs, suggesting a correlation between infiltration
of both adaptive (TIL) and innate (TAM) cell populations.
While use of multiparameter flow cytometric analysis of
ex vivo tissue specimens gives more quantitative measure-
ments of cell populations than traditional immunohisto-
chemical techniques, the anatomical location of the cell
populations of interest are lost. Accordingly, we per-
formed immunofluorescent staining of tissue that
included the tumor/parenchyma border, in order to deter-
mine better where TAMs were located in tumor-bearing
mice. Immunofluorescent staining of CD11b in animals
with late stage disease shows a robust population of TAMs
along the tumor border and within the highly cellular
tumor (Figure 1.C).
While our initial experiments demonstrated that TAMs
outnumbered TILs early after tumor implantation, it
remained unclear whether this was true throughout the
course of tumor growth. Furthermore, we were interested
to test if these cells maintained their functional activity,
and what immunological changes were occurring system-
ically. This last question was of interest given that
increases of Tregs have been observed in many tumors,
including GBMs [22,25-29](CEM, unpublished observa-
tions), and there is evidence that Tregs may function in
part by suppressing APC activity. We thus performed a
more comprehensive study that investigated immunolog-
ical changes both systemically and within the tumor
microenvironment, which included an evaluation of the
function of TAMs isolated from ex vivo tumor specimens.BMC Immunology 2009, 10:11 http://www.biomedcentral.com/1471-2172/10/11
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Mice were examined after tumor implantation at early
(day 13), intermediate (day 26), and late (day 40 or signs
of tumor morbidity) stages of disease.
Within the periphery, we assessed the IFN-γ production in
T cells, as this is the major immunostimulatory cytokine
in this cell population. There was a modest increase in the
proportion of IFN-γ-producing CD4+ T cells (5.1% vs.
8.2%, P = 0.015) between the early and intermediate time
points examined, with these frequencies elevated through
the course of disease (5.1% vs. 7.7%, P = 0.011) (Figure
2). In contrast, more profound changes were observed in
the frequency and function of Tregs (CD4+FoxP3+ T cells)
in the periphery (Figure 3). The proportion of Tregs
among CD4+ T cells increased substantially between the
early and intermediate time points (9.0% vs. 15.2%, P =
0.0007), and remained elevated, though with a slight
decrease from the peak frequency, throughout the course
of disease (Figure 3A). Noteworthy was that the propor-
tion of Tregs expressing IL-10, the major immunoinhibi-
tory cytokine in this cell population, increased between
the early and intermediate time points (3.9% vs. 6.9%, P
= 0.020), with a decrease in this frequency by the final
time point (6.9% vs. 4.2%, P = 0.080) (Figure 3B).
Detection of tumor-infiltrating lymphocytes (TILs) and  tumor-associated macrophages and microglia (TAMs) in ex  vivo tumor specimens Figure 1
Detection of tumor-infiltrating lymphocytes (TILs) 
and tumor-associated macrophages and microglia 
(TAMs) in ex vivo tumor specimens. (A) Flow cytome-
tryic analysis and gating strategy used to detect TILs 
(CD3+CD45+ cells) and TAMs (CD11b+CD45+ cells) in brain. 
The initial gate excludes data points with extreme side and 
forward scatter properties. (B) The frequency of TILs and 
TAMs as obtained by flow cytometry was increased in ex vivo 
tumor specimen. Note that the TAMs shown here were 
detected by CD45. (C) Immunofluorescent staining of ex vivo 
tumor specimen revealed a large number of TAMs in the 
tumor specimen as compared to neighboring white matter. 
Rhodamine (red) staining for CD11b indicating TAMs, Hoe-
scht (blue) staining for nuclei. The increased cellularity on the 
left side of the image is grossly visible tumor tissue, and the 
right side of the image is white matter without gross tumor 
involvement.
Peripheral immunomodulation over the course of tumor  growth Figure 2
Peripheral immunomodulation over the course of 
tumor growth. Splenocytes were stained for extracellular 
CD4 and intracellular IFN-g expression. The proportion of 
CD4+ T cells expressing IFN-γ changes over the course of 
tumor development. Between the early and intermediate 
timepoint, the proportion of IFN-γ-producing splenic CD4+ T 
cells increased (5.1% vs. 8.2%, P = 0.015), and remained ele-
vated (5.1% vs. 7.7%, P = 0.011). 13 mice were analyzed at 13 
dpi (n = 4), 26 dpi (n = 4), and at 29 dpi upon exhibiting clini-
cal tumor morbidity (n = 1) or at 40 dpi (n = 4). Differences 
between the means at each time point were tested using 
two-sided t tests with unequal variances. *, P < 0.05; **, P < 
0.01, ***, P < 0.001.BMC Immunology 2009, 10:11 http://www.biomedcentral.com/1471-2172/10/11
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TILs were defined as cells present within ex vivo tumor
specimens that expressed both CD3 and CD45 (Figures 1
and 4). Between the early and intermediate time points,
there were no observed changes in TIL frequency (0.2% vs.
0.3%) (Figure 4A). However, later in the course of disease,
when comparing the intermediate and late time points, an
increase in TIL frequency was observed (0.3% vs. 2.0%, P
= 0.047) (Figure 4A). Among these CD3+CD45+ TILs, we
observed a decrease between the early/intermediate and
the late time point in the proportion of TILs that were
CD4+ (76.5% vs. 47.5%, P = 0.0003), suggesting that alter-
nate T cell subsets may be infiltrating the tumor microen-
vironment, such as CD8+ CTLs or NK T cells (Figure 4B).
Peripheral changes in frequency and function of CD4+FoxP3+  Treg cells Figure 3
Peripheral changes in frequency and function of 
CD4+FoxP3+ Treg cells. Splenocytes were stained for 
extracellular CD4 and intracellular FoxP3 and IL-10 expres-
sion. (A) An increase in Treg cell frequency among CD4+ T 
cells was observed between the early and intermediate time 
points (9.0% vs. 15.2%, P = 0.0007) and this frequency 
remained elevated at the late time point. (B) While the pro-
portion of Tregs expressing IL-10 increased between the 
early and intermediate time points (3.9% vs. 6.9%, P = 0.02), 
the proportion of IL-10-producing Tregs at the late time 
point returned to levels measured at the early time point 
(4.2%). 13 mice were analyzed at 13 dpi (n = 4), 26 dpi (n = 
4), and at 29 dpi upon exhibiting clinical tumor morbidity (n = 
1) or at 40 dpi (n = 4). Differences between the means at 
each time point were tested using a Mann-Whitney test. *, P 
< 0.05; **, P < 0.01, ***, P < 0.001.
Frequency of tumor-infiltrating lymphocytes (TILs) in ex vivo  tumor specimens over the course of tumor development Figure 4
Frequency of tumor-infiltrating lymphocytes (TILs) 
in ex vivo tumor specimens over the course of tumor 
development. Specimens were obtained prior to and at 
three time-points following tumor induction and stained for 
CD3, CD4, and CD45 expression. (A) An increase in the fre-
quency of TILs as characterized by CD3 and CD45 expres-
sion was observed at the late time-point (0.3% vs. 2.0%, P = 
0.047). (B) The percentage of CD4+ T cells among TILs was 
reduced at the late time point (76.5% vs. 47.5%, P = 0.0003). 
13 mice were analyzed at 13 dpi (n = 4), 26 dpi (n = 4), and at 
29 dpi upon exhibiting clinical tumor morbidity (n = 1) or at 
40 dpi (n = 4). Differences between the means at each time 
point were tested using two-sided t tests with unequal vari-
ances. *, P < 0.05; **, P < 0.01, ***, P < 0.001.BMC Immunology 2009, 10:11 http://www.biomedcentral.com/1471-2172/10/11
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We again quantified the frequencies of TAMs, this time
over the course of tumor growth and with the more spe-
cific APC-marker combination of CD45 and CD11b.
Moreover, these cells were assessed for secretion of TNF-α
and IL-10, the major immunostimulatory and immunoin-
hibitory cytokines from this cell population, respectively.
Between the early and intermediate time points, very little
change in TAM frequency was observed (2.0% vs. 1.1%).
Between the intermediate and final time points, however,
there was a substantial increase in frequency of TAMs
(1.1% vs. 5.6%, P = 0.017) (Figure 5). Of greatest interest,
there was no observed change in the proportion of TAMs
secreting TNF-α ex vivo between the early and intermedi-
ate time points (24.7% vs. 25.2%), but at the late stages of
tumor growth, a 2.5-fold reduction in the proportion of
these TAMs expressing TNF-α was observed (25.2% vs.
10.9%, P = 0.007) (Figure 5). No changes in IL-10 expres-
sion were detected (data not shown).
Discussion
In this study we report on the dynamics of central and
peripheral immunomodulation in a murine glioma
model. The most notable change within the tumor micro-
environment was an increase in TAM frequency over the
course of tumor growth, which correlated with functional
impairment, demonstrated by a decreased proportion of
TNF-α-secreting cells after mitogenic stimulation of ex vivo
TAMs. TIL frequency also increased during tumor growth,
with a decline in the relative proportion of CD4+ T cells
among the TIL population. In the periphery, consistent
with other tumor models that include glioma models
[22,26,28,29], the proportion of Tregs in the spleen
increased substantially relatively early in tumor develop-
ment, which was accompanied by increased frequencies
of IL-10-expressing Tregs. There was a modest increase in
IFN-γ-secreting CD4+ T cells throughout the course of
tumor growth.
Prior studies in humans and animal models have shown
the frequency of TAMs to be higher than that of APCs in
non-tumor-bearing brain [15] (DEA, unpublished obser-
vations). Our findings are consistent with these observa-
tions, and may represent local microglial proliferation,
microglial migration into the tumor, and infiltration by
peripheral monocytes with subsequent differentiation to
a macrophage or microglial phenotype. Previous studies
have demonstrated that TAMs have an immunosuppres-
sive phenotype, unable to promote T cell activation [16].
Our study has extended these observations by demon-
strating that a tumoricidal function of TAMs, namely
secretion of TNF-α, is lost at a relatively late point in
tumor growth.
Tregs have been implicated in the complex immunomod-
ulatory phenomena of gliomas [22,26,28,29], CEM
unpublished observations). Prior studies in humans have
shown an increased fraction of Tregs centrally and periph-
erally [21,24,25], but it is unclear if this is an early event,
with a potential for assisting in tumor progression, or a
late event, suggesting that the Tregs may be epiphenome-
nological. Our study suggests that the peripheral Treg
population is increased relatively early in tumor develop-
ment, raising important questions about the role of these
cells in tumor progression. Previous studies have shown
TILs to consist of a higher proportion of Tregs compared
to CNS lymphocytes not associated with gliomas [27].
Although this was not assessed in the present study, we
did observe that the relative proportion of CD4+ T cells
among TILs decreased over time. Although the frequency
of CD8+ T cells was not addressed in these samples, it is
likely that the overwhelming majority of these CD4- TILs
are CD8+ T cells. It will be important in future studies to
determine if these are indeed CTLs, or an alternate popu-
lation of immunosuppressive T cells [30].
The increase of Treg frequency observed in this study
occurs relatively early compared to the observed CNS
effects. In fact, between the intermediate and final time
points examined in the course of tumor growth, when all
observed CNS changes occur, the peripheral Treg propor-
tion actually decreases, though still elevated from base-
line. A similar effect is seen in the proportion of Tregs
expressing IL-10. These data suggest that the peripheral
immunosuppressive effects may occur prior to the local
effects present in the tumor microenvironment. Indeed, it
Frequency and functional changes in tumor-associated mac- rophages and microglia (TAMs) in ex vivo tumor specimens  over the course of tumor development Figure 5
Frequency and functional changes in tumor-associ-
ated macrophages and microglia (TAMs) in ex vivo 
tumor specimens over the course of tumor develop-
ment. While the percentage of TAMs (CD11b+CD45+ cells) 
was increased by the final time-point (1.1% vs. 5.6%, P = 
0.017), their functional capacity was impaired as measured by 
TNF-a expression (25.2% vs. 10.9%, P = 0.007). 13 mice were 
analyzed at 13 dpi (n = 4), 26 dpi (n = 4), and at 29 dpi upon 
exhibiting clinical tumor morbidity (n = 1) or at 40 dpi (n = 
4). Differences between the means at each time point were 
tested using two-sided t tests with unequal variances. *, P < 
0.05; **, P < 0.01, ***, P < 0.001.BMC Immunology 2009, 10:11 http://www.biomedcentral.com/1471-2172/10/11
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is tempting to speculate that tumor infiltrating Tregs may
contribute to the loss of TAM function later in the course
of disease.
Conclusion
In conclusion, this study represents to our knowledge the
first detailed kinetic analysis of the frequency and func-
tion of TAMs present in gliomas. Our discovery that the
function of TAMs is not affected until relatively late in
tumor growth suggests that a therapeutic window may
exist in which to preserve the function of these cells, and
potentially have a positive clinical effect on glioma out-
come.
Methods
Tumor Model
All animal care and experiments involved with this work
follow internationally recognized guidelines and are over-
seen by the Columbia University Institutional Animal
Care and Use Committee (Columbia University IACUC
Protocol # AC-AAAA6721).
Several studies have shown that PDGF-expressing retrovi-
rus will induce the formation of glial tumors in mice
[31,32]. Our lab has generated a murine glioma model,
similar to our rat model [33], by injecting PDGF-express-
ing retrovirus into the white matter of adult BALB/c mice
(CEM, unpublished). Our reasons for use of this model
are several. Use of a syngeneic tumor model such as ours
is essential to appropriately characterize the interactions
of the tumor with the immune system, as syngeneity con-
fers MHC expression recognizable by the animals' adap-
tive immune systems, as well as avoids induction of an
immune response to exogenous foreign antigen. Histolog-
ically, these tumors closely resemble GBM, demonstrating
palisading necrosis, vascular proliferation, and migration
and infiltration by the tumor cells. Considering the high
frequency of immune cells at the borders of these tumors,
these infiltrative characteristics make this a particularly
strong model for gaining insight into the interactions
between GBM and the immune system. We have shown
that these tumor cells can be isolated and injected into
naïve mice for several generations, producing consistent
tumor formation.
Briefly, a total of 1 × 105 tumor cells were injected into the
right frontal white matter of 13 adult BALB/c mice. All
mice were female, between 7 and 8 weeks old, and pur-
chased from Jackson Laboratory (Bar Harbor, ME). In the
first series of experiments, 4 mice were injected with
tumor cells and then analyzed at 10 dpi. In a subsequent,
more comprehensive series of experiments, 13 mice were
analyzed at 13 dpi (n = 4), 26 dpi (n = 4), and at 29 dpi
upon exhibiting clinical tumor morbidity (n = 1) or at 40
dpi (n = 4); the mouse that became symptomatic at 29 dpi
was included with the animals studied at 40 dpi. Mice
were anesthetized with ketamine and xylazine, sacrificed,
and spleens and brains were harvested.
Splenocyte Preparation
Fresh spleens were dissociated into single cell suspensions
through a 70 μm filter in culture medium (MEM alpha
medium with 2ME, Penicillin/Streptomycin/Amphoter-
icin, and 10% FBS). Culture medium and supplies were
purchased from Invitrogen (Carlsbad, CA). Cells were
stimulated with 5 nM PMA, 1 mM Ionomycin, and 0.1%
monensin solution (eBioscience, San Diego, CA) and
incubated at 37°C for 9 hours.
Tumor Preparation
Tumors were dissected and mechanically as well as enzy-
matically dissociated with trypsin, papain, and DNAse.
Samples were filtered through 70 μm mesh to create single
cell suspensions. These suspensions were purified using a
sucrose gradient at 2000 rpm for 20 min to remove neu-
rons and blood, and resuspended. Cells were stimulated
with 1 μM LPS and 0.1% monensin and incubated at
37°C for 7.5 hrs.
Flow Cytometry
Splenocytes and tumor cell preparations were washed
with PBS/2% FBS and 0.01% monensin, spun again, and
resuspended in 100 μl of this medium. Cell surface stain-
ing was performed at room temperature, in the dark, for
20 min. Splenocytes were stained using FITC-conjugated
anti-mouse CD8, PerCP-conjugated anti-mouse CD3, and
Pacific Blue-conjugated anti-mouse CD4 monoclonal
antibodies. Tumor cell preparations were stained using
PE-conjugated anti-mouse CD11b, PerCP-conjuaged anti-
mouse CD45, APC-conjugated anti-mouse CD3, Pacific
Blue-conjugated anti-mouse CD4, and Pacific Blue-conju-
gated anti-mouse CD3 monoclonal antibodies. Cells were
washed once in PBS/2% FBS and 0.1% monensin, then
resuspended in 200 μL of Fix/Perm solution (BD Bio-
science, San Jose, CA) at 4°C for 30 min. They were then
washed twice in permeabilization buffer (BD Bioscience,
saponin, FBS), and stained for cytokines and FoxP3 at 4°C
for 30 min. For intracellular stainining, splenocytes were
stained using PE-FoxP3, APC-IFN-γ, and APC-IL-10 anti-
bodies. Tumor cell preparations were stained using APC-
conjugated anti-mouse TNF-a and APC-conjugated anti-
mouse IL-10 antibodies. The cell preparations were then
washed twice in Perm buffer (BD Bioscience) and resus-
pended in PBS/2% FBS. All antibodies for intracellular
and cell surface staining were purchased from eBioscience
(San Diego, CA), except for PerCP-conjugated anti-mouse
CD45, which was purchased from BD Bioscience (San
Jose, CA).BMC Immunology 2009, 10:11 http://www.biomedcentral.com/1471-2172/10/11
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Multiparameter flow cytometry data were collected on an
LSR II (BD Biosciences) and analyzed using FlowJo ver-
sion 8.7.1 (Tree Star, Ashland, OR). As lymphocytes are a
large proportion of the splenocyte preparation, there is a
reliable and recognizable cluster with the expected for-
ward and side scatter properties, around which the initial
gates were created. However, due to the relatively small
population of TILs within the tumor/CNS preparation,
serial dilutions of splenocytes with tumor preparations
were made to derive a lymphocyte gate in tumor prepara-
tions. This gate was then applied to the pure tumor prep-
arations for all TIL analyses.
Immunofluorescence
In separate BALB/c mice injected with the same tumor
cells in the same fashion outlined above, tumors were
grown until tumor morbidity was apparent. Mice were
then anesthetized with ketamine and xylazine, sacrificed,
perfused with PBS, then PBS with 4% paraformaldehyde.
Brains were harvested and kept in 4% paraformaldehyde
for 24 hours, then stored in increasing concentrations of
glucose in PBS up to 30%. The brains were then frozen,
sliced, and mounted on glass slides. For indirect immun-
ofluorescence labeling, sections were pre-incubated with
buffered blocking solution (PBS containing 10% horse
serum, 0.5% triton and NaN3 in dilution of 1:500) for 1
hr at room temperature. Sections were subsequently incu-
bated with rat anti-mouse CD11b primary antibody (eBi-
oscience, San Diego, CA) diluted 1:100 in buffered
blocking solution at room temperature overnight. Subse-
quently, sections were thoroughly washed (5 × 3 mins) in
PBS and incubated in solutions of rhodamine-conjugated
goat anti-rat IgG secondary antibody (Jackson Immuno-
logical, West Grove, PA) in buffered blocking solution for
1 hr at room temperature. After incubation, sections were
thoroughly washed again in PBS (5 × 3 mins) and incu-
bated with Hoescht stain for five minutes for nuclear vis-
ualization. Sections were washed in PBS again and rinsed
with distilled water.
Statistical Analyses
Where appropriate, means of proportions were compared
using two-tailed Student's t-tests with unequal variances.
For analyses of small proportions (< 0.05), logarithmi-
cally transformed data were analyzed using one-way
ANOVA, and parameters with statistically significant
ANOVA results were analyzed further using two-tailed
Student's t-tests. P-values less than 0.05 were considered
significant for all analyses.
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